Nasdaq · CIK 0001062822
LXRX LEXICON PHARMACEUTICALS, INC.
Insider trading from SEC Form 4. Last filing Jun 4, 2026. Close $1.68 on Oct 9, 2026, +47% from the 52-week low and -36% from the high.
LEXICON PHARMACEUTICALS, INC. (LXRX) has 61 SEC Form 4 filings on file from 14 insiders, the latest filed on Jun 4, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
5 open-market trades have been scored at LXRX. The newest: Raymond Debbane (director) bought $2,980 of stock on Feb 25, 2026, filed Feb 27, 2026, scored 15 (weak). The largest of the 5 shown: Invus Global Management, LLC (director and 10% owner) bought $2.0M on Feb 2, 2026, scored 56 (moderate). 2 insiders bought within 14 days of each other around Feb 13, 2026.
LXRX closed at $1.68 on Oct 9, 2026, 47% above its 52-week low and 36% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at LEXICON PHARMACEUTICALS, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Raymond Debbane director buy | $2,980 2,000 shares | +0% | - | |
| 34Weak | Raymond Debbane director buy | $147k 100,000 shares | +6% | - | |
| 35Weak | Raymond Debbane director buy | $220k 150,000 shares | +9% | - | |
| 41Moderate | Raymond Debbane director buy | $353k 268,497 shares | +19% | - | |
| 56Moderate | Invus Global Management, LLC director, owner buy | $2.0M 1,538,462 shares | - | - |
Transactions
The newest 50 of 173 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | Philippe Amouyal director | MOption exercise Common Stock | +89,312 | $0.00 | $0 | 374,486 | Jun 4, 2026 |
| Jun 3, 2026 | Raymond Debbane director | MOption exercise Common Stock | +89,312 | $0.00 | $0 | 1,995,498 | Jun 4, 2026 |
| Jun 3, 2026 | Ivan Cheung director | MOption exercise Common Stock | +89,312 | $0.00 | $0 | 89,312 | Jun 4, 2026 |
| Jun 3, 2026 | Sam L Barker director | MOption exercise Common Stock | +89,312 | $0.00 | $0 | 213,771 | Jun 4, 2026 |
| Jun 3, 2026 | Philippe Amouyal director | MOption exercise Restricted Stock Unitsderivative | -89,312 | $0.00 | $0 | 0 | Jun 4, 2026 |
| Jun 3, 2026 | Ivan Cheung director | MOption exercise Restricted Stock Unitsderivative | -89,312 | $0.00 | $0 | 0 | Jun 4, 2026 |
| Jun 3, 2026 | Sam L Barker director | MOption exercise Restricted Stock Unitsderivative | -89,312 | $0.00 | $0 | 0 | Jun 4, 2026 |
| Jun 3, 2026 | Raymond Debbane director | MOption exercise Restricted Stock Unitsderivative | -89,312 | $0.00 | $0 | 0 | Jun 4, 2026 |
| Apr 30, 2026 | Artal Participations S.a r.l. director, owner | MOption exercise Common Stockindirect: See Footnotes | +20,421,735 | $0.00 | $0 | 175,156,062 | May 8, 2026 |
| Apr 30, 2026 | Artal Participations S.a r.l. director, owner | AGrant or award Series B Convertible Preferred Stockderivativeindirect: See Footnotes | +408,435 | - | - | 408,435 | May 8, 2026 |
| Apr 30, 2026 | Artal Participations S.a r.l. director, owner | MOption exercise Series B Convertible Preferred Stockderivativeindirect: See Footnotes | -408,435 | $0.00 | $0 | 0 | May 8, 2026 |
| May 1, 2026 | Sam L Barker director | AGrant or award Restricted Stock Unitsderivative | +35,714 | $0.00 | $0 | 35,714 | May 4, 2026 |
| May 1, 2026 | Philippe Amouyal director | AGrant or award Restricted Stock Unitsderivative | +35,714 | $0.00 | $0 | 35,714 | May 4, 2026 |
| May 1, 2026 | Ivan Cheung director | AGrant or award Restricted Stock Unitsderivative | +35,714 | $0.00 | $0 | 35,714 | May 4, 2026 |
| May 1, 2026 | Raymond Debbane director | AGrant or award Restricted Stock Unitsderivative | +35,714 | $0.00 | $0 | 35,714 | May 4, 2026 |
| May 1, 2026 | Raymond Debbane director | AGrant or award Stock Option (Right to Buy)derivative | +43,478 | $0.00 | $0 | 43,478 | May 4, 2026 |
| May 1, 2026 | Philippe Amouyal director | AGrant or award Stock Option (Right to Buy)derivative | +43,478 | $0.00 | $0 | 43,478 | May 4, 2026 |
| May 1, 2026 | Sam L Barker director | AGrant or award Stock Option (Right to Buy)derivative | +43,478 | $0.00 | $0 | 43,478 | May 4, 2026 |
| May 1, 2026 | Ivan Cheung director | AGrant or award Stock Option (Right to Buy)derivative | +43,478 | $0.00 | $0 | 43,478 | May 4, 2026 |
| Feb 28, 2026 | Michael Exton Chief Executive Officer | MOption exercise Common Stock | +503,263 | - | - | 503,263 | Mar 3, 2026 |
| Feb 28, 2026 | Suma Gopinathan SVP, Discovery | MOption exercise Common Stock | +14,000 | - | - | 88,520 | Mar 3, 2026 |
| Feb 28, 2026 | Scott M Coiante SVP, Chief Financial Officer | MOption exercise Common Stock | +160,237 | - | - | 160,237 | Mar 3, 2026 |
| Feb 28, 2026 | Craig B Granowitz SVP, Chief Medical Officer | MOption exercise Common Stock | +35,790 | - | - | 156,042 | Mar 3, 2026 |
| Feb 28, 2026 | Brian T Crum SVP, General Counsel & Secr. | MOption exercise Common Stock | +33,457 | - | - | 363,658 | Mar 3, 2026 |
| Feb 28, 2026 | Wendy McDermott SVP, Human Resources | MOption exercise Common Stock | +27,697 | - | - | 149,343 | Mar 3, 2026 |
| Feb 28, 2026 | Rachel Yap Martens SVP, Partnerships & Corp Strat | MOption exercise Common Stock | +67,090 | - | - | 67,090 | Mar 3, 2026 |
| Feb 28, 2026 | Lisa DeFrancesco SVP, IR and Corp Comm | MOption exercise Common Stock | +24,674 | - | - | 40,251 | Mar 3, 2026 |
| Feb 28, 2026 | Wendy McDermott SVP, Human Resources | MOption exercise Common Stock | +52,316 | - | - | 201,659 | Mar 3, 2026 |
| Feb 28, 2026 | Michael Exton Chief Executive Officer | FTax withholding Common Stock | -204,831 | $1.47 | $301k | 298,432 | Mar 3, 2026 |
| Feb 28, 2026 | Suma Gopinathan SVP, Discovery | MOption exercise Common Stock | +20,310 | - | - | 108,830 | Mar 3, 2026 |
| Feb 28, 2026 | Scott M Coiante SVP, Chief Financial Officer | FTax withholding Common Stock | -54,881 | $1.47 | $81k | 105,356 | Mar 3, 2026 |
| Feb 28, 2026 | Craig B Granowitz SVP, Chief Medical Officer | MOption exercise Common Stock | +74,226 | - | - | 230,268 | Mar 3, 2026 |
| Feb 28, 2026 | Brian T Crum SVP, General Counsel & Secr. | MOption exercise Common Stock | +69,386 | - | - | 330,201 | Mar 3, 2026 |
| Feb 28, 2026 | Rachel Yap Martens SVP, Partnerships & Corp Strat | FTax withholding Common Stock | -35,826 | $1.47 | $53k | 31,264 | Mar 3, 2026 |
| Feb 28, 2026 | Lisa DeFrancesco SVP, IR and Corp Comm | MOption exercise Common Stock | +128,190 | - | - | 168,441 | Mar 3, 2026 |
| Feb 28, 2026 | Lisa DeFrancesco SVP, IR and Corp Comm | FTax withholding Common Stock | -74,572 | $1.47 | $110k | 93,869 | Mar 3, 2026 |
| Feb 28, 2026 | Michael Exton Chief Executive Officer | MOption exercise Restricted Stock Unitsderivative | -503,263 | - | - | 1,006,527 | Mar 3, 2026 |
| Feb 28, 2026 | Rachel Yap Martens SVP, Partnerships & Corp Strat | MOption exercise Restricted Stock Unitsderivative | -67,090 | - | - | 134,180 | Mar 3, 2026 |
| Feb 28, 2026 | Suma Gopinathan SVP, Discovery | MOption exercise Common Stock | +65,640 | - | - | 174,470 | Mar 3, 2026 |
| Feb 28, 2026 | Wendy McDermott SVP, Human Resources | MOption exercise Common Stock | +144,393 | - | - | 346,052 | Mar 3, 2026 |
| Feb 28, 2026 | Scott M Coiante SVP, Chief Financial Officer | MOption exercise Restricted Stock Unitsderivative | -160,237 | - | - | 320,473 | Mar 3, 2026 |
| Feb 28, 2026 | Craig B Granowitz SVP, Chief Medical Officer | MOption exercise Common Stock | +202,260 | - | - | 432,528 | Mar 3, 2026 |
| Feb 28, 2026 | Brian T Crum SVP, General Counsel & Secr. | MOption exercise Common Stock | +170,163 | - | - | 533,821 | Mar 3, 2026 |
| Feb 28, 2026 | Lisa DeFrancesco SVP, IR and Corp Comm | MOption exercise Restricted Stock Unitsderivative | -24,674 | - | - | 24,673 | Mar 3, 2026 |
| Feb 28, 2026 | Suma Gopinathan SVP, Discovery | FTax withholding Common Stock | -24,338 | $1.47 | $36k | 150,132 | Mar 3, 2026 |
| Feb 28, 2026 | Wendy McDermott SVP, Human Resources | FTax withholding Common Stock | -68,107 | $1.47 | $100k | 277,945 | Mar 3, 2026 |
| Feb 28, 2026 | Craig B Granowitz SVP, Chief Medical Officer | FTax withholding Common Stock | -109,098 | $1.47 | $160k | 323,430 | Mar 3, 2026 |
| Feb 28, 2026 | Brian T Crum SVP, General Counsel & Secr. | FTax withholding Common Stock | -105,019 | $1.47 | $154k | 428,802 | Mar 3, 2026 |
| Feb 28, 2026 | Lisa DeFrancesco SVP, IR and Corp Comm | MOption exercise Restricted Stock Unitsderivative | -128,190 | - | - | 256,380 | Mar 3, 2026 |
| Feb 28, 2026 | Suma Gopinathan SVP, Discovery | MOption exercise Restricted Stock Unitsderivative | -14,000 | - | - | 0 | Mar 3, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Philippe Amouyaldirector
- Artal Participations S.a r.l.director, owner
- Sam L Barkerdirector
- Ivan Cheungdirector
- Scott M CoianteSVP, Chief Financial Officer
- Brian T CrumSVP, General Counsel & Secr.
- Raymond Debbaneowner, director
- Lisa DeFrancescoSVP, IR and Corp Comm
- Michael ExtonChief Executive Officer
- Suma GopinathanSVP, Discovery
- Craig B GranowitzSVP, Chief Medical Officer
- Invus Global Management, LLCowner, director
- Rachel Yap MartensSVP, Partnerships & Corp Strat
- Wendy McDermottSVP, Human Resources
Questions about LXRX
Answered from the filings on this page, as of the latest one.
Are insiders buying LXRX?
No. In the last 90 days no insider at LEXICON PHARMACEUTICALS, INC. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade LXRX on the open market?
Raymond Debbane (director) bought $2,980 of LXRX on Feb 25, 2026 and filed the Form 4 on Feb 27, 2026. InsiderTell scored 15 (weak).
How many insiders file Form 4 at LEXICON PHARMACEUTICALS, INC.?
14 people have filed a Form 4 at LEXICON PHARMACEUTICALS, INC., among them Philippe Amouyal (director), Artal Participations S.a r.l. (director and 10% owner), Sam L Barker (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.